Viroxime

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

General description Vigreux indents run the entire length of the column and act as the packing for the column.

ApplicationWB: 1/2,000-1/20,000 : Predicted molecular weight: 54 kDaFlow: 0.016 μg/mL – 2 μg/mLICC/IF: 2 μg/mL.

ApplicationWB: 1/2,000-1/20,000 : Predicted molecular weight: 54 kDaFlow: 0.016 μg/mL – 2 μg/mLICC/IF: 2 μg/mL.

ApplicationWB: 1/2,000-1/20,000 : Predicted molecular weight: 54 kDaFlow: 0.016 μg/mL – 2 μg/mLICC/IF: 2 μg/mL.

ApplicationWB: 1/2,000-1/20,000 : Predicted molecular weight: 54 kDaFlow: 0.016 μg/mL – 2 μg/mLICC/IF: 2 μg/mL.

ApplicationWB: 1/2,000-1/10,000 : Predicted molecular weight: 54 kDaFlow: 0.008 μg/mL – 1 μg/mLICC/IF: 2 μg/mL.

ApplicationWB: 1/2,000-1/10,000 : Predicted molecular weight: 54 kDaFlow: 0.008 μg/mL – 1 μg/mLICC/IF: 2 μg/mL.

Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin ( VIM ), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and

Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin ( VIM ), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and

Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin ( VIM ), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and

Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin ( VIM ), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and